Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Nov;135(5):1172-1192.
doi: 10.1016/j.bja.2025.07.079. Epub 2025 Sep 12.

Use of prothrombin complex concentrates in liver transplantation: a systematic review and meta-analysis

Affiliations
Meta-Analysis

Use of prothrombin complex concentrates in liver transplantation: a systematic review and meta-analysis

Isabella Kojundzic et al. Br J Anaesth. 2025 Nov.

Abstract

Background: Liver transplantation (LT) can be a high transfusion procedure. Frozen plasma (FP) is widely used despite mixed efficacy and safety data. Several centres perform LT with no or low volume of FP by using prothrombin complex concentrate (PCC). This systematic review and meta-analysis characterises the existing efficacy and safety data of PCC use in LT.

Methods: This review was registered (PROSPERO CRD#42024561866). MEDLINE, Embase, Cochrane, and ClinicalTrials.gov were searched from inception to 30 May 2024. Studies in adults undergoing LT where PCC exposure was reported in relation to clinical outcomes were included. Random effects models were used to obtain pooled effect estimates.

Results: All studies were retrospective, with seven reporting the number of patients receiving PCC [392/1901 (21%)], and one grouping patients receiving different factor concentrates together [576/939 (61%)]. Patients receiving PCC had worse preoperative coagulopathy, model for end-stage liver disease scores, and comorbidities. Patients exposed to PCC had a comparable mean number of red blood cell (RBC), plasma, or platelet units transfused. Use of viscoelastic testing-based algorithms incorporating PCC compared with usual care was associated with reduced odds of RBC exposure (odds ratio [OR]: 0.53, 95% confidence interval [CI]: 0.32-0.86, I2=0%) and FP exposure (OR: 0.35, 95% CI: 0.13-0.92, I2=50%), but not platelets. Safety outcomes were driven by one large study using PCC as rescue therapy.

Conclusions: Although there are no randomised trials comparing use of PCC vs FP in LT, their efficacy and safety appear comparable. Higher-quality studies are needed to assess PCC use for coagulopathic bleeding in LT.

Keywords: blood coagulation disorders; blood transfusion; end-stage liver disease; liver transplantation; prothrombin complex concentrates.

PubMed Disclaimer

Conflict of interest statement

Declarations of interest JB was supported in part by a merit award from the Department of Anaesthesiology and Pain Medicine, University of Toronto; has received research funding or honoraria from Octapharma, Grifols, and Canadian Blood Services. KG works as the Medical Director of Tem Innovations, Munich, Germany, and received lecture fees from Octapharma, Lachen, Switzerland. KK was supported in part by a merit award from the Department of Anesthesiology and Pain Medicine, University of Toronto; has received research support, honoraria, or consultancy for speaking. JC has received research support from CSL Behring, Octapharma, and Canadian Blood Services. SM has received honoraria from Octapharma and Instrumentation Laboratory. All co-authors contributed to the critique, selection, and interpretation of included studies. All studies were reviewed by at least two individuals without disclosures or financial conflicts of interest (NA, IK). The other authors declare no conflict of interest.

Figures

Fig 1
Fig 1
PRISMA flow diagram. PCC, prothrombin complex concentrate.
Fig 2
Fig 2
Forest plots for transfusion outcomes and adverse events.,, , ,, CI, confidence interval; OR, odds ratio; PCC, prothrombin complex concentrate.

References

    1. Lisman T., Caldwell S.H., Burroughs A.K., et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol. 2010;53:362–371. - PubMed
    1. Bezinover D., Dirkmann D., Findlay J., et al. Perioperative coagulation management in liver transplant recipients. Transplantation. 2018;102:578–592. - PubMed
    1. Biancofiore G., Blasi A., De Boer M.T., et al. Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE) Minerva Anestesiol. 2019;85:782–798. - PubMed
    1. Kovalic A.J., Khan M.A., Malaver D., et al. Thromboelastography versus standard coagulation testing in the assessment and reversal of coagulopathy among cirrhotics: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32:291–302. - PubMed
    1. Yoon U., Bartoszko J., Bezinover D., et al. Intraoperative transfusion management, antifibrinolytic therapy, coagulation monitoring and the impact on short-term outcomes after liver transplantation-a systematic review of the literature and expert panel recommendations. Clin Transplant. 2022;36 - PubMed

MeSH terms

Substances